


Claims

1. A compound of formula (I)



I

and pharmaceutically acceptable salts thereof, in which

R^1 and R^2 independently represent phenyl, thienyl or pyridyl each of which is independently optionally substituted by one or more groups represented by Z;

Z represents a C_{1-3} alkyl group optionally substituted by one or more: hydroxy; a C_{1-6} alkoxy group optionally substituted by one or more fluoro; a C_{3-8} cycloalkyl group; a saturated or partially unsaturated 5 to 8 membered heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen or sulphur; or by a group $NR^{10}R^{11}$ (in which R^{10} and R^{11} independently represent hydrogen, a C_{1-6} alkyl group, a C_{1-6} alkanoyl group or a C_{1-6} alkoxycarbonyl group), or Z represents a C_{3-8} cycloalkyl group, a C_{1-6} alkoxy group (optionally substituted by one or more fluoro), hydroxy, halo, trifluoromethyl, trifluoromethylthio, trifluoromethylsulphonyl, nitro, a group $NR^{10}R^{11}$ (in which R^{10} and R^{11} independently represent hydrogen, a C_{1-6} alkyl group, a C_{1-6} alkanoyl group or a C_{1-6} alkoxycarbonyl group), mono or di C_{1-3} alkylamido, C_{1-3} alkylthio, C_{1-3} alkylsulphonyl, C_{1-3} alkylsulphonyloxy, C_{1-3} alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3} alkyl carbamoyl, sulphamoyl, acetyl, an aromatic heterocyclic group which is optionally substituted by one or more halo, C_{1-4} alkyl, trifluoromethyl or trifluoromethoxy and a saturated or partially unsaturated 5 to 8 membered heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen or sulphur wherein the heterocyclic group is optionally substituted by one or more C_{1-3} alkyl groups, hydroxy, fluoro, benzyl or an amino group $-NR^xR^y$ in which R^x and R^y independently represent H or C_{1-4} alkyl;

R^3 represents a group of formula $X-Y-NR^5R^6$

in which X is CO or SO₂

and Y is absent or represents NH optionally substituted by a C₁₋₃alkyl group

and R^5 and R^6 independently represent:

5 a C₁₋₆alkyl group optionally substituted by one or more hydroxy;

an (amino)C₁₋₄alkyl- group in which the amino is optionally substituted by one or more C₁₋₃alkyl groups;

10 a group (C₃₋₁₂cycloalkyl)(CH₂)_g- wherein g is 0, 1, 2 or 3 wherein the cycloalkyl is optionally substituted by one or more fluoro, hydroxy, C₁₋₃alkyl, C₁₋₃alkoxy, trifluoromethyl or trifluoromethoxy;

a group -(CH₂)_r(phenyl)_s in which r is 0, 1, 2, 3 or 4, s is 1 when r is 0 otherwise s is 1 or 2 and the phenyl groups are optionally independently substituted by one or more groups represented by Z;

naphthyl;

15 anthracenyl;

a saturated or partially unsaturated 5 to 8 membered heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen or sulphur wherein the heterocyclic group is optionally substituted by one or more C₁₋₃alkyl groups, hydroxy, fluoro, trifluoromethyl, benzyl or an amino group -NR^xR^y in which R^x and R^y independently represent H or C₁₋₄alkyl ;

1-adamantylmethyl;

a group - (CH₂)_t Het in which t is 0, 1, 2, 3 or 4, and the alkylene chain is optionally substituted by one or more C₁₋₃alkyl groups and Het represents an aromatic heterocyclic group optionally substituted by one, two or three groups selected from a C₁₋₃alkyl group, a

25 C₁₋₅alkoxy group or halo;

or R^5 represents H and R^6 is as defined above;

or R^5 and R^6 together with the nitrogen atom to which they are attached represent a saturated or partially unsaturated 5 to 8 membered heterocyclic group containing one nitrogen and optionally one of the following: oxygen, sulphur or an additional nitrogen;

30 wherein the heterocyclic group is optionally substituted by one or more more C₁₋₃alkyl

groups, hydroxy, fluoro, trifluoromethyl, trifluoromethoxy, benzyl, C₁₋₆alkanoyl or an amino group -NR^xR^y in which R^x and R^y independently represent H or C₁₋₄alkyl;

R⁴ represents a group of formula (CH₂)_nCOOR⁷

in which n is 0, 1, 2, 3 or 4; and R⁷ represents a C₄₋₁₂alkyl group, a C₃₋₁₂cycloalkyl group or a (C₃₋₁₂cycloalkyl)C₁₋₃alkyl- group each of which is optionally substituted by one or more of the following: a C₁₋₆alkyl group; fluoro, amino or hydroxy, or

R⁷ represents a group -(CH₂)_aphenyl in which a is 0, 1, 2, 3 or 4 and the phenyl group is optionally substituted by one or more groups represented by Z which may be the same or different or

R⁷ represents a saturated or partially unsaturated 5 to 8 membered heterocyclic group containing one or more of the of the following: oxygen, sulphur or nitrogen; wherein the heterocyclic group is optionally substituted by one or more C₁₋₃alkyl groups, C₁₋₃acyl groups, hydroxy, amino or benzyl; or

R⁴ represents a group of formula -(CH₂)_o-O-(CH₂)_p- R⁸ in which o and p independently represent an integer 0, 1, 2, 3 or 4 and each of the alkyl chains is independently optionally substituted by one or more C₁₋₆alkyl groups, C₁₋₆alkoxy groups or hydroxy and R⁸ represents a C₁₋₁₂alkyl group or a C₁₋₁₂alkoxy group or R⁸ represents phenyl optionally independently substituted by one or more Z groups or R⁸ represents an aromatic heterocyclic group or a saturated or partially unsaturated 5 to 8 membered heterocyclic group containing one or more of one following: oxygen, sulphur or nitrogen wherein each of these rings is optionally substituted by one or more groups represented by Z which may be the same or different; with the proviso that R⁴ is not a C₁₋₃alkoxymethyl group unless R³ represents a group of formula X-YNR⁵R⁶ in which X is CO and Y is absent and R⁵ is H and R⁶ is a C₃₋₈ cycloalkyl group substituted by one or more fluoro or X is CO and Y is NH and NR⁵R⁶ together represent a piperidino group substituted by one or more fluoro; or R⁸

represents a C₃₋₈cycloalkyl group or a C₃₋₈cycloalkenyl group optionally substituted by one or more groups represented by Z which may be the same or different;

R⁴ represents a C₄₋₁₂alkyl group optionally substituted by one or more fluoro, hydroxy, or amino; or

R⁴ represents a group of formula -(CH₂)_qR⁹ in which q is 0, 1, 2, 3 or 4 and R⁹ represents a C₃₋₁₂cycloalkyl group, a C₃₋₁₂cycloalkenyl group, phenyl, an aromatic heterocyclic group or a saturated or partially unsaturated 5 to 8 membered heterocyclic group containing one or more of one following: oxygen, sulphur or nitrogen wherein each of these rings is optionally substituted by one or more groups represented by Z which may be the same or different; or


R⁴ represents a group of formula -L¹R⁹ in which L¹ represents a C₂₋₆alkenylene chain optionally substituted by one or more C₁₋₄alkyl groups and R⁹ is as previously defined; or

R⁴ represents a group of formula -(CH₂)_m-O-(CO)-R¹⁰ in which m represents an integer 0, 1, 2, 3 or 4, in which R¹⁰ represents a C₁₋₁₂alkyl group optionally substituted by one or more fluoro, hydroxy, or amino or R¹⁰ represents a group of formula -(CH₂)_qR⁹ in which q and R⁹ is as previously described; or

R⁴ represents a group of formula CONR¹¹R¹² in which R¹¹ and R¹² independently represent H or a C₁₋₈alkyl group or a C₁₋₈alkyl group substituted by one or more hydroxy groups provided that at least one of R¹¹ and R¹² is a hydroxyC₁₋₈alkyl group; or

R⁴ represents a group of formula -L²CN in which L² represents a C₁₋₆alkylene chain.

2. A compound according to claim 1 represented by formula IIa



11a

wherein R^1 and R^2 independently represent phenyl optionally independently substituted by halo or pyridyl,

5 R^4 represents a C_{4-8} alkyl group, a group CH_2OR^8 in which R^8 is a C_{4-8} alkyl group, a group CO_2R^7 in which R^7 represents a C_{4-8} alkyl group, and Y is represents NH and

R^5 represents H and

R^6 represents perfluorophenyl or phenyl optionally substituted by trifluoromethyl or R^5 and

10 R^6 together with the nitrogen to which they are attached represent piperidino, morpholino or piperazino each of which is optionally substituted by one or more C_{1-3} alkyl groups, hydroxy, fluoro, trifluoromethyl, trifluoromethoxy, benzyl, C_{1-6} alkanoyl or an amino group $-NR^xR^y$ in which R^x and R^y independently represent H or C_{1-4} alkyl;

15 or Y is absent and


R^5 represents H or a C_{1-6} alkyl group optionally substituted by amino;

R^6 represents tetrahydropyranyl or 4- piperidinyl optionally substituted by one or more C_{1-3} alkyl groups, hydroxy, fluoro, trifluoromethyl, trifluoromethoxy, benzyl, C_{1-6} alkanoyl or an amino group $-NR^xR^y$ in which R^x and R^y independently represent H or C_{1-4} alkyl or a C_{1-6} alkyl group optionally substituted by amino;

20 or

R^5 and R^6 together with the nitrogen to which they are attached represent piperidino, morpholino or piperazino each of which is optionally substituted by C_{1-3} alkyl or fluoro.

3. A compound according to claim 1 represented by formula IIb




IIb

wherein R¹ and R² represent phenyl independently optionally substituted by one or more chloro; and

R⁷ represents butyl, *tert*-butyl, cyclohexyl or benzyl.

4. A compound according to claim 1 represented by formula IIc



IIc

wherein R¹ and R² represent phenyl independently optionally substituted by one or more chloro or methyl;

u is 0, 1, 2, 3, or 4;

R^l represents triazolyl, tetrazolyl, imidazolyl, pyrrolyl, thiazolyl, oxazolyl, oxazinolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, azolactonyl or azetidiny each of which is optionally substituted by one or more of the following: morpholinyl, piperidinyl, pyrrolidinyl, a C₁₋₃alkylthio group, a C₃₋₆cycloalkyl group, C₁₋₃alkoxy, hydroxy, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, or a C₁₋₆alkyl group optionally substituted by one or more of the following: C₁₋₃alkoxy, hydroxy, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, morpholinyl, piperidinyl or pyrrolidinyl or a group of formula CH(X)R^pR^q in which X is hydroxy, a C₁₋₆alkoxy group, difluoromethoxy, C₁₋₆alkyl, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, morpholinyl, piperidinyl or pyrrolidinyl, R^p represents hydrogen, a C₁₋₆alkyl

group or a C₃₋₆cycloalkyl group and R^q represents hydrogen, a C₁₋₆alkyl group or a C₃₋₆cycloalkyl group or R^j represents C₁₋₆alkoxy group terminally substituted on carbon by one or more fluoro; and

R^k represents piperidino, 4,4-difluorocyclohexyl or C₃₋₆alkyl optionally substituted by hydroxy.

5. A compound according to claim 4 in which R¹ and R² represent phenyl independently optionally substituted by one or more chloro or methyl;

R^j represents triazolyl or tetrazolyl each of which is optionally substituted by one or more of the following: a C₁₋₃alkylthio group, a C₃₋₆cycloalkyl group or a C₁₋₆alkyl group optionally substituted by one or more of the following: C₁₋₃alkoxy, hydroxy, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, morpholinyl, piperidinyl or pyrrolidinyl or a group of formula CH(X)R^pR^q in which X is hydroxy, difluoromethoxy, C₁₋₆alkyl, amino C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, morpholinyl, piperidiyl or pyrrolidinyl, R^p represents hydrogen, a C₁₋₆alkyl group or a C₃₋₆cycloalkyl group and R^q represents hydrogen, a C₁₋₆alkyl group or a C₃₋₆cycloalkyl group or R^j represents C₁₋₆alkoxy group terminally substituted on carbon by one or more fluoro; and u is 0 or 1; and

R^k represents piperidino, 4,4-difluorocyclohexyl or C₃₋₆alkyl optionally substituted by hydroxy.

6. A compound selected from one or more of the following:

tert-butyl 5,6-bis(4-chlorophenyl)-3-[(piperidin-1-ylamino)carbonyl]pyrazine-2-carboxylate;

butyl 5,6-bis(4-chlorophenyl)-3-[(piperidin-1-ylamino)carbonyl]pyrazine-2-carboxylate;

cyclohexyl 5,6-bis(4-chlorophenyl)-3-[(piperidin-1-ylamino)carbonyl]pyrazine-2-carboxylate;

benzyl 5,6-bis(4-chlorophenyl)-3-[(piperidin-1-ylamino)carbonyl]pyrazine-2-carboxylate;

tert-butyl 5,6-bis(4-chlorophenyl)-3-([cis-2-hydroxycyclohexyl]amino)carbonyl)pyrazine-2-carboxylate;

tert-butyl 5,6-bis(4-chlorophenyl)-3-([trans-2-hydroxycyclohexyl]amino)carbonyl)pyrazine-2-carboxylate;

tert-butyl 5,6-bis(4-chlorophenyl)-3-({2-[4-(trifluoromethyl)phenyl]hydrazino}carbonyl)-pyrazine-2-carboxylate;

tert-butyl 5,6-bis(4-chlorophenyl)-3-[(morpholin-4-ylamino)carbonyl]pyrazine-2-carboxylate;

5 tert-butyl 5,6-bis(4-chlorophenyl)-3-({2-[4-(tert-butylhydrazino)carbonyl]pyrazine-2-carboxylate};

3-(tert-butoxymethyl)-5,6-bis(4-chlorophenyl)-N-piperidin-1-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-(cyclohexylidenemethyl)-N-piperidin-1-ylpyrazine-2-carboxamide;

10 5,6-bis(4-chlorophenyl)-3-(cyanomethyl)-N-piperidin-1-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-(1-methoxyethyl)-N-piperidin-1-ylpyrazine-2-carboxamide

tert-butyl 5,6-bis(4-chlorophenyl)-3-[(2-hydroxy-1-methylethyl)amino]carbonyl)-pyrazine-2-carboxylate;

15 tert-butyl 5,6-bis(4-chlorophenyl)-3-[(4,4-difluorocyclohexyl)amino]carbonyl)pyrazine-2-carboxylate;

tert-butyl 5,6-bis(4-chlorophenyl)-3-[(pentylamino)carbonyl]pyrazine-2-carboxylate;

tert-butyl 5,6-bis(4-chlorophenyl)-3-[(1-ethylpropyl)amino]carbonyl)pyrazine-2-carboxylate;

20 tert-butyl 5,6-bis(4-chlorophenyl)-3-[(4,4-difluoropiperidin-1-yl)amino]carbonyl)-pyrazine-2-carboxylate;

5,6-bis(4-chlorophenyl)-N-piperidin-1-yl-3-[(4-propyl-1H-1,2,3-triazol-1-yl)methyl]pyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-[[4-(1-hydroxyethyl)-1H-1,2,3-triazol-1-yl]methyl]-N-piperidin-1-ylpyrazine-2-carboxamide;

25 5,6-bis(4-chlorophenyl)-3-[[5-(1-hydroxyethyl)-1H-1,2,3-triazol-1-yl]methyl]-N-piperidin-1-ylpyrazine-2-carboxamide;

tert-butyl {[1-((5,6-bis(4-chlorophenyl)-3-[(piperidin-1-ylamino)carbonyl]pyrazin-2-yl)methyl)-1H-1,2,3-triazol-4-yl]methyl}carbamate;

30 tert-butyl {[1-((5,6-bis(4-chlorophenyl)-3-[(piperidin-1-ylamino)carbonyl]pyrazin-2-yl)methyl)-1H-1,2,3-triazol-5-yl]methyl}carbamate;

3-[[4-(aminomethyl)-1H-1,2,3-triazol-1-yl]methyl]-5,6-bis(4-chlorophenyl)-N-piperidin-1-ylpyrazine-2-carboxamide;

3-[[5-(aminomethyl)-1H-1,2,3-triazol-1-yl]methyl]-5,6-bis(4-chlorophenyl)-N-piperidin-1-ylpyrazine-2-carboxamide;

5 5,6-bis(4-chlorophenyl)-3-(phenoxymethyl)-N-piperidin-1-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-(morpholin-4-ylmethyl)-N-piperidin-1-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-(piperidin-1-ylmethyl)-N-piperidin-1-ylpyrazine-2-carboxamide;

10 5,6-bis(4-chlorophenyl)-3-[(cyclohex-2-en-1-yloxy)methyl]-N-piperidin-1-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-[(cyclohexyloxy)methyl]-N-piperidin-1-ylpyrazine-2-carboxamide;

15 5,6-bis(4-chlorophenyl)-N-(2-hydroxyethyl)-N'-piperidin-1-ylpyrazine-2,3-dicarboxamide;

5,6-bis(4-chlorophenyl)-N-(3-hydroxybutyl)-N'-piperidin-1-ylpyrazine-2,3-dicarboxamide;

5,6-bis(4-chlorophenyl)-N-(3-hydroxypropyl)-N'-piperidin-1-ylpyrazine-2,3-dicarboxamide;

20 *Tert*-butyl 5,6-bis(4-methylphenyl)-3-[(piperidin-1-ylamino)carbonyl]pyrazine-2-carboxylate;

5,6-bis(4-methylphenyl)-N-piperidin-1-yl-3-(1H-tetrazol-1-ylmethyl)pyrazine-2-carboxamide;

5,6-bis(4-methylphenyl)-N-piperidin-1-yl-3-(2H-tetrazol-2-ylmethyl)pyrazine-2-carboxamide;

25 5,6-bis(4-chlorophenyl)-N-piperidin-1-yl-3-(2H-tetrazol-2-ylmethyl)pyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-N-piperidin-1-yl-3-(1H-tetrazol-1-ylmethyl)pyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-*N*-(4,4-difluorocyclohexyl)-3-(2*H*-tetrazol-2-ylmethyl)pyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-*N*-(4,4-difluoropiperidin-1-yl)-3-(2*H*-tetrazol-2-ylmethyl)pyrazine-2-carboxamide;

5 5,6-bis(4-chlorophenyl)-3-[(2-methoxyethoxy)methyl]-*N*-piperidin-1-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-[(5-cyclopropyl-2*H*-tetrazol-2-yl)methyl]-*N*-piperidin-1-ylpyrazine-2-carboxamide;

10 5,6-bis(4-chlorophenyl)-3-[(5-cyclopropyl-1*H*-tetrazol-1-yl)methyl]-*N*-piperidin-1-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-[(5-methyl-2*H*-tetrazol-2-yl)methyl]-*N*-piperidin-1-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-[(5-methyl-1*H*-tetrazol-1-yl)methyl]-*N*-piperidin-1-ylpyrazine-2-carboxamide;

15 *tert*-butyl 6-(4-chlorophenyl)-5-(4-methylphenyl)-3-[(piperidin-1-ylamino)carbonyl]pyrazine-2-carboxylate;

tert-butyl 5-(4-chlorophenyl)-6-(4-methylphenyl)-3-[(piperidin-1-ylamino)carbonyl]pyrazine-2-carboxylate;

20 6-(4-chlorophenyl)-5-(4-methylphenyl)-*N*-piperidin-1-yl-3-(2*H*-tetrazol-2-ylmethyl)pyrazine-2-carboxamide;

5-(4-chlorophenyl)-6-(4-methylphenyl)-*N*-piperidin-1-yl-3-(2*H*-tetrazol-2-ylmethyl)pyrazine-2-carboxamide;

tert-butyl 5,6-bis(4-chlorophenyl)-3-[[2-hydroxyethyl)(methyl)amino]-carbonyl]pyrazine-2-carboxylate;

25 5,6-bis(4-chloro-phenyl)-3-propoxy-pyrazine-2-carboxylic acid piperidin-1-ylamide;

5,6-bis(4-chlorophenyl)-*N*-piperidin-1-yl-3-(2*H*-tetrazol-5-ylmethyl)pyrazine-2-carboxamide

5,6-bis(4-chlorophenyl)-*N*-piperidin-1-yl-3-(1*H*-tetrazol-5-yl)pyrazine-2-carboxamide;

30 5,6-bis(4-chlorophenyl)-3-[(5-morpholin-4-yl-2*H*-tetrazol-2-yl)methyl]-*N*-piperidin-1-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-[(5-morpholin-4-yl-1*H*-tetrazol-1-yl)methyl]-*N*-piperidin-1-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-*N*-piperidin-1-yl-3-[(5-pyrrolidin-1-yl-2*H*-tetrazol-2-yl)methyl]pyrazine-2-carboxamide;

5 5,6-bis(4-chlorophenyl)-*N*-piperidin-1-yl-3-[(5-pyrrolidin-1-yl-1*H*-tetrazol-1-yl)methyl]pyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-[[5-(methylthio)-2*H*-tetrazol-2-yl]methyl]-*N*-piperidin-1-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-[[5-(methylthio)-1*H*-tetrazol-1-yl]methyl]-*N*-piperidin-1-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-*N*-(4,4-difluorocyclohexyl)-3-(methoxymethyl)pyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-*N*-(4,4-difluorocyclohexyl)-3-[[4-fluorobenzyl]oxy]methyl]pyrazine-2-carboxamide;

15 5,6-bis(4-chlorophenyl)-3-[(4,4-difluoropiperidin-1-yl)methyl]-*N*-piperidine-1-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-*N*-(4,4-difluorocyclohexyl)-3-[(4,4-difluoropiperidin-1-yl)methyl]pyrazine-2-carboxamide; or

5,6-bis(4-chlorophenyl)-*N*-(4,4-difluoropiperidin-1-yl)-3-(methoxymethyl)pyrazine-2-carboxamide;

20 and pharmaceutically acceptable salts thereof.

7. A compound of formula I as claimed in any previous claim for use as a medicament.

25 8. A pharmaceutical formulation comprising a compound of formula I, as defined in any one of claims 1 to 6 and a pharmaceutically acceptable adjuvant, diluent or carrier.

9. Use of a compound of formula I according to any one of claims 1 to 6 in the preparation of a medicament for the treatment or prophylaxis of obesity, psychiatric disorders such as psychotic disorders, schizophrenia and bipolar disorders, anxiety, anxiodepressive disorders, depression, cognitive disorders, memory disorders, obsessive-compulsive disorders, anorexia, bulimia, attention disorders, epilepsy, and related


conditions, and neurological disorders such as dementia, neurological disorders, Parkinson's Disease, Huntington's Chorea and Alzheimer's Disease, immune, cardiovascular, reproductive and endocrine disorders, septic shock, diseases related to the respiratory and gastrointestinal systems, and extended abuse, addiction and/or relapse indications.

10. A method of treating obesity, psychiatric disorders, psychotic disorders, schizophrenia and bipolar disorders, anxiety, anxio-depressive disorders, depression, cognitive disorders, memory disorders, obsessive-compulsive disorders, anorexia, bulimia, attention disorders, epilepsy, and related conditions, neurological disorders, neurological disorders, Parkinson's Disease, Huntington's Chorea and Alzheimer's Disease, immune, cardiovascular, reproductive and endocrine disorders, septic shock, diseases related to the respiratory and gastrointestinal system, and extended abuse, addiction and/or relapse indications, comprising administering a pharmacologically effective amount of a compound of formula I according to claim 1 to a patient in need thereof.

11. A compound as defined in any one of claims 1 to 6 for use in the treatment of obesity.


12. A compound as defined in any one of claims 1 to 6 in combination with another pharmaceutically active compound.

13. A process to prepare a compound of formula I according to claim 1 comprising
a) reacting a compound of formula III




III

in which R¹, R² and R⁴ are as previously defined with an amine of formula IV



in which Y, R⁵ and R⁶ are as previously defined in a solvent, in the presence of a coupling agent and optionally in the presence of a base at a temperature in the range of -25°C to 150°C to give compounds of formula I in which R¹, R² and R⁴ are as previously defined and R³ is COYNR⁵R⁶ as previously defined, or

b) reacting an azide of formula XI




in which R¹, R² and R³ are as previously defined with an acetylene of formula XII



XII


in which Z is as previously defined in an inert solvent and optionally in the presence of a catalyst at a temperature in the range of -25°C to 150°C to give compounds of formula I in which R¹, R² and R³ are as previously defined and R⁴ represents a group CH₂(1H-1,2,3-triazol-1-yl) in which the triazole is optionally substituted on carbon by Z; or

c) reacting a compound of formula XIV



XIV


in which R¹, R² and R⁴ are as previously defined and R⁶ represents an alkyl group with an amine of formula IV



or a salt thereof in which Y, R⁵ and R⁶ are as previously defined in a solvent in the presence of a coupling agent and optionally in an inert atmosphere at a temperature in the


range of -25°C to 150°C to give compounds of formula I in which R^1 , R^2 and R^4 are as previously defined and R^3 is COYNR^5R^6 ; or

d) reacting a compound of formula XV



XV

in which R^1 , R^2 and R^4 are as previously defined and X represents a leaving group with an amine of formula IV




IV

or a salt thereof in which Y, R^5 and R^6 are as previously defined in a solvent optionally in the presence of a base at a temperature in the range of -25°C to 150°C to give compounds of formula I in which R^1 , R^2 and R^4 are as previously defined and R^3 is COYNR^5R^6 ; or

d) de-protecting compounds of formula I, in which one or more groups is protected, to give a compounds of formula I.

14. A compound of formula XI



XI

in which R^1 , R^2 and R^3 are as previously defined.